Meeting
2018 ASCO Annual Meeting
Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.
Authors
Volker Moebus
Department of Gynecology and Obstetrics, Klinikum Frankfurt Höchst, Academic Hospital of the Goethe University Frankfurt, Frankfurt, Germany
Volker Moebus , Stefanie Noeding , Ekkehart Ladda , Peter Klare , Marcus Schmidt , Andreas Schneeweiss , Wolfgang Janni , Frederik Marmé , Toralf Reimer , Sabine Schmatloch , Elmar Stickeler , Michael Untch , Bruno Valentin Sinn , Volkmar Müller , Peter A. Fasching , Gunter Von Minckwitz , Jenny Furlanetto , Nicole Burchardi , Sibylle Loibl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT01690702
Citation
J Clin Oncol 36, 2018 (suppl; abstr 568)
DOI
10.1200/JCO.2018.36.15_suppl.568
Abstract #
568
Poster Bd #
60
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).
First Author: Andreas Schneeweiss
Poster
2013 ASCO Annual Meeting
Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2).
First Author: Volker Moebus
Poster
2020 ASCO Virtual Scientific Program
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).
First Author: Volker Moebus
Poster
2017 ASCO Annual Meeting
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
First Author: Xavier B. Pivot